Adaptive proton therapy pediatric solid tumors Hodgkin's lymphoma
Summary
ClinicalTrials.gov registered a new Phase 2 interventional study (NCT07514819) evaluating adaptive proton therapy for pediatric patients with solid tumors and Hodgkin's lymphoma. The single-arm trial will assess treatment response rates, survival outcomes, and treatment-related toxicity in pediatric oncology patients. The study is sponsored by the University of Pennsylvania and will enroll approximately 40 participants.
What changed
A new clinical trial registration entry was added to ClinicalTrials.gov documenting a Phase 2 study on adaptive proton therapy for pediatric solid tumors and Hodgkin's lymphoma. The trial will evaluate treatment efficacy and safety parameters in approximately 40 pediatric patients.
For clinical investigators and healthcare providers, this represents an additional ongoing research option for pediatric oncology patients. The registration fulfills sponsor obligations under FDAAA 801 for clinical trial disclosure requirements.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.